Background: Non–vitamin K oral anticoagulants (NOACs) do not require routine laboratory
monitoring. However, laboratory measurement may be desirable in special situations and …

Direct oral anticoagulants (DOAC) have shown an upward prescribing trend in recent years
due to favorable pharmacokinetics and pharmacodynamics without requirement for routine …

Background Three novel direct oral anticoagulants (DOACs) have recently been registered
by the Food and Drug Administration and European Medicines Agency Commission …

Atrial fibrillation (AF) is the commonest sustained cardiac arrhythmia and is associated with
significant morbidity and mortality. There is plenty of evidence available to support the …

The direct acting oral anticoagulants (DOAC s), including dabigatran, rivaroxaban,
apixaban, and edoxaban, have favorable pharmacokinetic and pharmacodynamic …

Activation of the blood coagulation cascade leads to fibrin deposition and platelet activation
that are required for hemostasis. However, aberrant activation of coagulation can lead to …

A new generation of antithrombotic agents, which are conventionally known as direct oral
anticoagulants (DOACs), have recently emerged and are continuing to be developed. These …

A new generation of antithrombotic agents has recently emerged. These provide direct
inhibition of either thrombin (factor IIa [FIIa]) or FXa, and are increasingly replacing the …

Direct oral anticoagulants (DOAC s), including the direct thrombin inhibitor, dabigatran, and
the direct factor Xa (FX a) inhibitors, rivaroxaban, apixaban and edoxaban, are approved for …

Although the non-vitamin K antagonist oral anticoagulants (NOACs) do not require routine
monitoring, there are special circumstances in which laboratory measurement may be …